Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices used to deliver it.
Through its complaint made public on Tuesday in the U.S. District Court in Wilmington, Delaware, Sanofi is seeking to halt Lilly's proposed commercial marketing in the United States of a rival treatment, known as Abasria, saying the sale would violate its rights.
Sanofi's lawsuit, and a narrower lawsuit filed in January, came after Lilly and German partner Boehringer Ingelheim Corp last December said they had applied with the U.S. Food and Drug Administration to sell a generic version of Lantus, whose active ingredient is insulin glargine.
http://in.reuters.com/article/2014/07/08/us-elililly-sanofi-lawsuit-idINKBN0FD20720140708
Through its complaint made public on Tuesday in the U.S. District Court in Wilmington, Delaware, Sanofi is seeking to halt Lilly's proposed commercial marketing in the United States of a rival treatment, known as Abasria, saying the sale would violate its rights.
Sanofi's lawsuit, and a narrower lawsuit filed in January, came after Lilly and German partner Boehringer Ingelheim Corp last December said they had applied with the U.S. Food and Drug Administration to sell a generic version of Lantus, whose active ingredient is insulin glargine.
http://in.reuters.com/article/2014/07/08/us-elililly-sanofi-lawsuit-idINKBN0FD20720140708